<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03413865</url>
  </required_header>
  <id_info>
    <org_study_id>OTN Study</org_study_id>
    <nct_id>NCT03413865</nct_id>
  </id_info>
  <brief_title>Telemedicine Clinic for Prostate Cancer Patients</brief_title>
  <official_title>A Pilot Study of a Nurse and Pharmacist Led OTN (Ontario Telemedicine Network) Based Clinic for Management of Prostate Cancer Patients on Oral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grand River Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grand River Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, open label study will evaluate a nurse and pharmacist led clinic conducted
      remotely from Grand River Regional Cancer Centre at Grand River Hospital (GRRCC/GRH) using
      OTN teleconferencing as a platform for patients with prostate cancer receiving oral
      chemotherapy agents.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient satisfaction with overall care</measure>
    <time_frame>2 Years</time_frame>
    <description>The primary outcome will be a comparison of patient satisfaction with overall care utilizing a validated scale between the group of patients using the OTN clinic and a group of control patients receiving conventional care at GRRCC</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cancer, Treatment-Related</condition>
  <arm_group>
    <arm_group_label>OTN virtual clinic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacist and nurse led OTN based remote teleconference based clinic (OTN) The OTN clinic will be conducted by providing the patient with a link via email which will allow the patient to access OTN teleconferencing and meet virtually with a pharmacist and nurse during a previously scheduled appointment. Virtual clinic appointments will be 30 minutes long and will consist of a patient assessment and open ended questions about the patient health status using a modified version of the validated MOATT (MASCC Oral Agent Teaching Tool) created by the Multidisciplinary Association of Supportive Care in Cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In person Visits</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients are followed in person at the cancer clinic based on standard of care guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Visits conducted via Telemedicine</intervention_name>
    <description>Patients will be followed via telemedicine with visits lead by a Pharmacist and a Nurse</description>
    <arm_group_label>OTN virtual clinic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male over 18 years of age with prostate cancer receiving oral treatment with
             abiraterone or enzalutamide.

          2. Ability to provide consent to study.

          3. Willingness to complete study questionnaires and a semi-structured exit interview.

          4. Adequate command of the English language to complete study questionnaire and survey.

          5. Access to technology to allow a link to the virtual telemedicine clinic. (excluding
             control group)

          6. Willingness to participate in videoconference with pharmacist or nurse from their home
             environment. (excluding control group)

        Exclusion Criteria:

          1. Patients receiving oral anti-cancer therapy other than abiraterone and enzalutamide.

          2. Patients lacking the technology at home to participate in the virtual telemedicine
             clinic. (excluding control group)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate Cancer Patients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stacey Hubay, MD, FRCPC</last_name>
    <phone>519-749-4370</phone>
    <phone_ext>2307</phone_ext>
    <email>stacey.hubay@grhosp.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carla Girolametto, MA, MHSC</last_name>
    <phone>519-749-4370</phone>
    <phone_ext>2307</phone_ext>
    <email>carla.girolametto@grhosp.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Grand River Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Girolametto</last_name>
      <phone>5197494370</phone>
      <phone_ext>2307</phone_ext>
      <email>carla.girolametto@grhosp.on.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

